All In Biotech

Drug Trial Radar · NCT06820099

Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS-7535 in Subjects With Heart Failure, Mild Reduction/Preservation of Ejection Fraction, and Obesity

Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

Apr 10, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Feb 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel design phase II clinical trial, including a screening period of up to 2 weeks, a 36-weeks' treatment period, and a 1-week safety follow-up visit period.

Conditions

  • Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

Interventions

  • HRS-7535 tabletDrug

    HRS-7535 tablet.

  • HRS-7535 tablet placeboDrug

    HRS-7535 tablet placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage change from baseline in body weight.Time frame: At week 36.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.